Focus of the month - Alzheimer's Disease
New GLP-1 weight loss drugs are about to ship to more American homes
Le laboratoire danois Novo Nordisk va investir 2,1 milliards d'euros à Chartres - Le Parisien
Alerte sur l'Ozempic, un antidiabétique détourné pour perdre du poids
IJMS | Free Full-Text | Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
Daniel J Drucker on X: "Based on the early promising data for injectable cagrilintide-semaglutide combination for #obesity #T2D @novonordisk move to test an oral GLP-1 Amylin Amycretin peptide in healthy PPL with
Type 2 Diabetes and the Role of GLP-1 | Diabetes Education for Patients | novoMEDLINK™
Novo Nordisk promotes new GLP-1 receptor agonist to fight diabetes, obesity < Pharma < Article - KBR
The Now Generation & New Generation of GLP-1 RAs: Reshaping the Care of T2DM
ᐅ What are GLP-1 agonists? • HealthExpress®
Wegovy (semaglutide) for Chronic Weight Management
Walmart, Coca-Cola Sink As GLP-1 Drugs Raise Alarms About Food Demand
Wegovy wows investors, sends ripples throughout GLP-1 developer space | BioWorld
J.P. Morgan doubles GLP-1 market projection to $71B in 2032
EMA will monitor suicide risk in Novo Nordisk's GLP-1 products
Novo Nordisk Gets Close to Launching the First Oral GLP-1 Drug for Diabetes
Novo Nordisk keeps GLP-1 expansion spree rolling with $2.3B manufacturing upgrade in France | Fierce Pharma
Analogue du GLP-1 hebdomadaire | Le Quotidien du Pharmacien
Novo Nordisk plans multi-billion Denmark manufacturing expansion
Another Weight-Loss Trial Win for Weekly GLP-1 Drug | MedPage Today
Werking van GLP-1
User-unfriendly Pen costs Sanofi lead on new Diabetes Drug Combo
FDA Approves First Oral GLP-1 RA
GLP-1 analogs, new trend in obesity treatment, become even more effective < Pharma < Article - KBR
